Effects of Ginsenoside on serum IL-17 and IL-23 in patients with systemic lupus erythematosus
10.3760/cma.j.issn.1008-6706.2014.08.011
- VernacularTitle:人参皂苷对系统性红斑狼疮患者血清IL-17和IL-23的影响
- Author:
Jianshe LI
;
Xiaoyan ZHANG
- Publication Type:Journal Article
- Keywords:
Systemic lupus erythematosus;
Ginsenoside;
Interleukin-17;
Interleukin-23
- From:
Chinese Journal of Primary Medicine and Pharmacy
2014;21(8):1147-1149
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effectiveness of Ginsenoside on serum IL-17 and IL-23 in patients with systemic lupus erythematosus.Methods According to the digital table,86 patients with systemic lupus erythematosus (SLE) were randomly divided into two groups,the control group (n =43 cases) and the observation group (n =43 cases).The patients in the control group were treated through prednisone,while the patients in the observation group were treated through prednisone plus ginsenoside.They were all treated for three months,systemic lupus erythematosus activity index(SLEDAI),serum complement 3 (C3),IL-17 and IL-23 were evaluated.Results SLEDAI after treatment were significantly decreased,compared with the control group,the observation group decreased more significantly (t =2.73,P ＜ 0.05).Mtertreatment,serum C3 were significantly elevated,compared with thecontrol group,the observation group increased more significantly(t =3.04,P ＜0.05).After treatment,serum IL-17 and IL-23 were significantly reduced,and after treatment compared with the control group,the observation group decreased more significantly (t =2.13,3.06,all P ＜ 0.05).The rates of adverse reactions were 25.6％ in the control group and 7.0％ in the observation group.There was a statistically significance between two groups (x2 =4.89,P ＜ 0.05).Conclusion Ginsenoside can decrease serum IL-17 and IL-23 in patients with systemic lupus erythematosus.
